Since increased thrombin activity may contribute to the pathogenesis of acute respiratory distress syndrome in SARS-CoV-2-infected individuals, the thrombin receptor PAR1 has also been proposed as a potential target for the therapy of COVID-19 [90]. Here, F2R is linked to COVID-19.